Cytokinetics Inc. Stock
Cytokinetics Inc. Stock
Cytokinetics Inc. gained 0.890% compared to yesterday.
The stock is an absolute favorite of our community with 38 Buy predictions and no Sell predictions.
As a result the target price of 72 € shows a positive potential of 27.43% compared to the current price of 56.5 € for Cytokinetics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Cytokinetics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | 0.890% | 5.660% | 1.818% | 27.273% | 4.673% | 33.971% | 185.714% |
| Biocryst Pharmaceuticals | 1.510% | 5.823% | -7.730% | -33.820% | -12.965% | -39.937% | -28.782% |
| Heron Therapeutics Inc. | 4.460% | -8.380% | -23.984% | -42.494% | -12.657% | -60.383% | -93.571% |
| Madrigal Pharmaceuticals inc. | -2.110% | -3.244% | -8.630% | 21.600% | -21.625% | 46.880% | 286.640% |
Comments
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $95.00 price target on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
News
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?
B. Lynne Parshall, Director at Cytokinetics, Incorporated (NASDAQ:CYTK), reported the sale of 5,000 shares in an open-market transaction valued at ~$323,650 on November 19, 2025; direct ownership
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly